CAS Registry Number raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-20. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
=== Other dermatological conditions === In addition to the approved use for treating acne vulgaris, researchers have investigated off-label applications for dermatological conditions, such as rosacea, psoriasis, and other conditions. Rosacea was reported as responding favorably to doses lower than used for acne. Isotretinoin in combination with ultraviolet light was shown affective for treating psoriasis. Isotretinoin in combination with injected interferon-alpha showed some potential for treating genital warts. Isotretinoin in combination with topical fluorouracil or injected interferon-alpha showed some potential for treating precancerous skin lesions and skin cancer.
== German Empire (1871–1918) == The German Empire was born out of the North German Confederation as result of the Franco-Prussian War (1870/71). The Präsidium (the Prussian king), which now had also the title Emperor, named the chancellor. Political parties: None Centre
==== MeSH D06.472.040 – adrenal cortex hormones ==== MeSH D06.472.040.502 – 17-ketosteroids MeSH D06.472.040.502.112 – androstenedione MeSH D06.472.040.502.195 – androsterone MeSH D06.472.040.502.497 – estrone MeSH D06.472.040.502.583 – etiocholanolone MeSH D06.472.040.502.620 – dehydroepiandrosterone MeSH D06.472.040.502.620.300 – dehydroepiandrosterone sulfate MeSH D06.472.040.585 – hydroxycorticosteroids MeSH D06.472.040.585.353 – 11-hydroxycorticosteroids MeSH D06.472.040.585.353.118 – aldosterone MeSH D06.472.040.585.353.237 – corticosterone MeSH D06.472.040.585.353.476 – hydrocortisone MeSH D06.472.040.585.353.500 – 18-hydroxycorticosterone MeSH D06.472.040.585.353.825 – tetrahydrocortisol MeSH D06.472.040.585.478 – 17-hydroxycorticosteroids MeSH D06.472.040.585.478.195 – cortisone MeSH D06.472.040.585.478.225 – cortodoxone MeSH D06.472.040.585.478.392 – hydrocortisone MeSH D06.472.040.585.478.782 – tetrahydrocortisol MeSH D06.472.040.585.478.865 – tetrahydrocortisone MeSH D06.472.040.585.611 – desoxycorticosterone MeSH D06.472.040.585.611.400 – 18-hydroxydesoxycorticosterone MeSH D06.472.040.585.745 – pregnenolone MeSH D06.472.040.585.745.500 – 17-alpha-hydroxypregnenolone
Sources: en.wikipedia.org
Locomotive. Vossloh Locomotives (owned by Chinese CRRC) manufactures three models of diesel-hydraulic (G6, G12, G18) and two models of diesel-electric (DE12, DE18) locomotives. Other manufacturer was Voith Turbo Lokomotivtechnik, but closed in 2014 year. Both firms are in Kiel.
=== Push vs pull === In consumer markets, another key strategic level decision is whether to use a push or pull strategy. In a push strategy, the marketer uses intensive advertising and incentives aimed at distributors, especially retailers and wholesalers, with the expectation that they will stock the product or brand, and that consumers will purchase it when they see it in stores. In contrast, in a pull strategy, the marketer promotes the product directly to consumers hoping that they will pressure retailers to stock the product or brand, thereby pulling it through the distribution channel. The choice of a push or pull strategy has important implications for advertising and promotion. In a push strategy, the promotional mix would consist of trade advertising and sales calls while the advertising media would normally be weighted toward trade magazines, exhibitions, and trade shows while a pull strategy would make more extensive use of consumer advertising and sales promotions while the media mix would be weighted toward mass-market media such as newspapers, magazines, television, and radio.
== Medicine == Muscle contraction, the physiological condition of a muscle which generates tension (traction) at its origin and insertion Uterine contraction, contraction of the uterus, such as during childbirth Contractility, the intrinsic ability of the heart/myocardium to contract Wound contraction, a stage in wound healing
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}{\frac {\partial \rho }{\partial t}}+\nabla \cdot \left(\rho \mathbf {u} \right)&=0\\\Longleftrightarrow \nabla \cdot \mathbf {u} &=-{\frac {1}{\rho }}{\frac {d\rho }{dt}}={\frac {1}{v}}{\frac {dv}{dt}}\end{aligned}}}
==== Online ==== Online backup storage is typically the most accessible type of data storage, and can begin a restore in milliseconds. An internal hard disk or a disk array (maybe connected to SAN) is an example of an online backup. This type of storage is convenient and speedy, but is vulnerable to being deleted or overwritten, either by accident, by malevolent action, or in the wake of a data-deleting virus payload.
Benzene is classified as a carcinogen, which increases the risk of cancer and other illnesses, and is also a notorious cause of bone marrow failure. Substantial quantities of epidemiologic, clinical, and laboratory data link benzene to aplastic anemia, acute leukemia, multiple myeloma, bone marrow abnormalities and cardiovascular disease. The specific hematologic malignancies that benzene is associated with include: acute myeloid leukemia (AML), aplastic anemia, myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML). Carcinogenic activity of benzene was discovered by Swedish pharmacologist C. G. Santesson in 1897 on female workers of a tire-making factory. The American Petroleum Institute (API) stated in 1948 that "it is generally considered that the only absolutely safe concentration for benzene is zero". There is no safe exposure level; even tiny amounts can cause harm. The US Department of Health and Human Services (DHHS) classifies benzene as a human carcinogen. Long-term exposure to excessive levels of benzene in the air causes leukemia, a potentially fatal cancer of the blood-forming organs. In particular, acute myeloid leukemia or acute nonlymphocytic leukemia (AML & ANLL) is caused by benzene. IARC rated benzene as "known to be carcinogenic to humans" (Group 1). As benzene is ubiquitous in gasoline and hydrocarbon fuels that are in use everywhere, human exposure to benzene is a global health problem.
==== Monetary policy ==== Since Castillo's victory in the first electoral round, the Sol has faced a precipitous fall in value against the dollar, due to fears of inflation and expropriations. As of 23 September 2021, the Sol had lost 12% of its value since the start of the year, making Peru's currency one of the worst performers among emerging markets. Castillo has sought to calm the markets by keeping Julio Velarde as the head of the Central Bank. During a speech before the OAS assembly, Castillo stated that his government is not communist and that he wouldn't expropriate anyone. Castillo stated that he didn't come to scare away investment, and invited big businesses to come to the country. Following Bellido's threat to nationalize the Camisea gas fields, the sol plunged once again. Afterward, Castillo replaced the Bellido cabinet with the Vásquez cabinet, which many have seen as a shift towards a more centrist administration. Following the new cabinet, the Sol began to recover its value, reaching a 10-week high as of 13 October 2021. However, after Castillo asked Congress to nationalize the Camisea gas fields, the Sol began to fall in value once again. On 9 November 2021, the Bank of America warned that almost all of Peru's inflation indicators are on red alert. They claimed that Peru's expectations "are set to exceed the upper limit of 3% of the Central Bank's target range of a two-year term." The Bank of America suggested that the Central Bank will have to tighten monetary policy.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.